This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Duchowny, M. Articles by Lamictal Pediatric Study Group Search for Related Content PubMed PubMed Citation Articles by Duchowny, M. Articles by Lamictal Pediatric Study Group, Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Epilepsy Social Bookmarking                         What's this?

Long-Term Tolerability and Efficacy of Lamotrigine in Pediatric Patients With Epilepsy

Department of Neurology Miami Children's Hospital, Miami, FL

Jamie Gilman, PharmD

Department of Neuroscience (Dr Gilman), Miami Children's Hospital, Miami, FL

John Messenheimer, MD

Department of Neurology Clinical Development GlaxoSmithKline, RTP, NC

Gilda Womble, MSPH

Department of Neurology Clinical Statistics GlaxoSmithKline, Research Triangle Park, NC

Marcus Risner, PhD

Department of Neurology Clinical Development GlaxoSmithKline, RTP, NC

Lamictal Pediatric Study Group

Accumulating data suggest that the antiepilepsy drug lamotrigine, which has been available for adult use for more than a decade, also confers broad-spectrum, well-tolerated control of epilepsy in children. The current study—the open-label continuation phase of several short-term clinical trials—was conducted to assess the long-term tolerability and efficacy of lamotrigine as open-label adjunctive therapy or monotherapy in pediatric patients for a variety of seizure types and syndromes including partial seizures, absence seizures, and Lennox-Gastaut syndrome. Clinic visits occurred every 24 weeks throughout the treatment period. A total of 252 patients under 16 years of age were enrolled in the study. The numbers of patients exposed to at least 48 weeks, 96 weeks, and 144 weeks of treatment with lamotrigine were 185 (73.4%), 119 (47.2%), and 60 (23.8%), respectively, for an average duration of exposure of 96.7 weeks. The most common adverse events considered by the investigator to be drug related were dizziness (9.1%), somnolence (7.9%), nausea (6.3%), vomiting (5.2%), and headache (5.2%). The most common serious adverse events (regardless of suspected cause) included pneumonia (3.0%) and infection (1.9%). Investigators judged that the overall clinical status of three-fourths of the patients had improved at treatment weeks 48 and 96 relative to prelamotrigine clinical status. Lamotrigine administered as monotherapy or adjunctive therapy for an average of 2 years (96.7 weeks) was well tolerated and effective in pediatric patients with partial or generalized epilepsy. These results complement and extend the large body of data demonstrating the tolerability and efficacy of lamotrigine with short- and long-term use in adults. (J Child Neurol 2002;17:278-285).

Journal of Child Neurology, Vol. 17, No. 4, 278-285 (2002)
DOI: 10.1177/088307380201700408


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. E. Pina-Garza, R. D. Elterman, R. Ayala, M. Corral, M. A. Mikati, M. J. Pina-Garza, C. R. Warnock, H. S. Conklin, and J. A. Messenheimer Long-term Tolerability and Efficacy of Lamotrigine in Infants 1 to 24 Months Old J Child Neurol, August 1, 2008; 23(8): 853 - 861. [Abstract] [PDF]

				T. A. Glauser Behavioral and Psychiatric Adverse Events Associated With Antiepileptic Drugs Commonly Used in Pediatric Patients J Child Neurol, August 1, 2004; 19(1_suppl): S25 - S38. [Abstract] [PDF]

				T. A. Glauser Behavioral and Psychiatric Adverse Events Associated With Antiepileptic Drugs Commonly Used in Pediatric Patients J Child Neurol, January 1, 2004; 19(1_suppl): S25 - S38. [Abstract] [PDF]